Tramadol — research review 1

...and this brings us to tramadol. It’s a weak opioid receptor agonist, but also acts like an SNRI, affecting serotonin and norepinephrine. It’s prescribed for pain relief, but the long-term picture is complex, especially concerning aging and mortality.

Right. We often think about the immediate pain relief, but what does the evidence say about its broader impact? Specifically, we’ve seen associations between chronic opioid use and increased all-cause mortality. For instance, a study in Public Health (2024) reported that chronic opioid use was linked to a 37% higher risk of all-cause mortality compared to short-term use.

And it’s not just the opioid component. Combining tramadol with gabapentinoids also raises concerns. Frontiers in Pharmacology (2022) found that this combination was associated with a 2.76 times increased risk of CNS depression and mortality. These are serious considerations for long-term treatment.

Absolutely. However, it's crucial to balance this with the fact that unrelieved chronic pain itself is detrimental. For example, GeroScience (2025) showed that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening. So, untreated pain can speed up biological aging.

The key is that while tramadol can offer necessary relief, the evidence about its long-term effects on biological aging and all-cause mortality, particularly concerning falls, sedation, or cognitive issues, is still developing. We don’t fully understand the direct causal links between tramadol and accelerated aging, or even if the observed mortality is purely due to the drug or underlying health conditions requiring its use.

Precisely. It’s about weighing the known benefits against potential long-term risks, and recognizing that there are still many unknowns about the precise mechanisms and long-term implications for biological aging markers like the epigenetic clock.